scholarly journals Pulmonary Talcosis in an Immunocompromised Patient

2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
Thanh-Phuong Nguyen ◽  
Sowmya Nanjappa ◽  
Manjunath Muddaraju ◽  
John N. Greene
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lymphoblastic Leukemia ◽  
Philadelphia Chromosome ◽  
Radiographic Findings ◽  
First Case ◽  
Causative Agents ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Immunocompromised State ◽  
Infectious Etiology

The first case of pulmonary talcosis or talc pneumoconiosis related to inhalation of talc during its extraction and processing in mines was described by Thorel in 1896. Pulmonary talcosis is most commonly seen secondary to occupational exposure or intravenous (IV) drug abuse and, occasionally, in excessive use of cosmetic talc. Based on literature review, there has been an increase in reported incidents of pulmonary talcosis due to various forms of exposure to the mineral. We report an 82-year-old man who is diagnosed with Philadelphia chromosome positive pre-B cell acute lymphoblastic leukemia (ALL) treated with palliative imatinib who presented with chronic hemoptysis and dyspnea shortly after his diagnosis. His symptoms were initially thought to be due to an infectious etiology due to his malignancy, immunocompromised state, and radiographic findings until high-resolution computerized tomographic (HRCT) findings showed a diffuse pulmonary fibrosis picture that prompted further questioning and a more thorough history inquiry on his exposure to causative agents of interstitial lung disease. Very often, patients do not recognize their exposure, especially in those whose exposure is unrelated to their occupation. Our case emphasizes the need for thorough and careful history taking of occupational and nonoccupational exposure to known causative agents of interstitial lung disease.

scholarly journals A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia

2018 ◽  
Vol Volume 11 ◽  
pp. 8589-8598 ◽  
Author(s):  
Raquel Vinhas ◽  
Alexandra Lourenço ◽  
Susana Santos ◽  
Marcos Lemos ◽  
Patrícia Ribeiro ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Philadelphia Chromosome ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Philadelphia Chromosome Positive

scholarly journals Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole

2018 ◽  
Vol 23 (5) ◽  
pp. 417-420 ◽  
Author(s):  
Mark John-Yung Lin ◽  
Megan Rose Paul ◽  
Dennis John Kuo
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Antifungal Agents ◽  
Chemotherapeutic Agent ◽  
Lymphoblastic Leukemia ◽  
Concomitant Administration ◽  
Potential Toxicity ◽  
Negative Interaction ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Immunocompromised State

Vincristine is a chemotherapeutic agent with a potential toxicity of sensorimotor peripheral neuropathy. Patients receiving chemotherapy are in an immunocompromised state and may require antifungal agents. Triazole antifungals are known inhibitors of cytochrome P450 (CYP) enzymes. Vincristine is a known CYP3A4 and CYP3A5 substrate, and concomitant administration with fluconazole or voriconazole has been reported to increase vincristine toxicity and peripheral neuropathy, but there is limited literature on posaconazole in this regard. This 5-year-old girl with pre–B-cell acute lymphoblastic leukemia received vincristine while receiving posaconazole for a mucormycosis infection and developed unexpectedly severe peripheral neuropathy. After recovery, the child continued on mucormycosis prophylaxis with posaconazole with instructions to hold for 2 days before and on the day of vincristine administration. This case illustrates the potentiating effect that posaconazole had on vincristine-associated neurotoxicity, and our approach to mitigating that negative interaction.

The first case of elderly TCF3-HLF-positive B-cell acute lymphoblastic leukemia

2019 ◽  
Vol 60 (11) ◽  
pp. 2821-2824 ◽  
Author(s):  
Reina Takeda ◽  
Kazuaki Yokoyama ◽  
Miho Ogawa ◽  
Toyotaka Kawamata ◽  
Tomofusa Fukuyama ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
First Case ◽  
Cell Acute Lymphoblastic Leukemia

scholarly journals Polymyositis-Dermatomyositis and Interstitial Lung Disease in Pregnant Woman Successfully Treated with Cyclosporine and Tapered Steroid Therapy

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
Saito Mayu ◽  
Sakiko Isojima ◽  
Yoko Miura ◽  
Shinichiro Nishimi ◽  
Mika Hatano ◽  
...  
Keyword(s):  
Pregnant Woman ◽  
Interstitial Lung Disease ◽  
Disease Activity ◽  
Lung Disease ◽  
Immunosuppressive Therapy ◽  
Steroid Therapy ◽  
Preterm Births ◽  
Successful Outcome ◽  
First Case ◽  
Immunosuppressant Regimen

Polymyositis-dermatomyositis is extremely rare during pregnancy, and immunosuppressive therapy should be administered after carefully considering the effects on both the mother and fetus. Several reports have associated the disease activity with fetal prognosis, higher rates of eclampsia, preterm births, and fetal deaths. We report our experience with a patient who was diagnosed with polymyositis-dermatomyositis complicated by interstitial lung disease during pregnancy and was treated with a combination-immunosuppressant regimen. To the best of our knowledge, this is the first case wherein cyclosporine was used concomitantly with a steroid for the treatment of polymyositis diagnosed during pregnancy, with successful outcome of childbirth without any complications.

scholarly journals An SFTPC gene mutation causes childhood interstitial lung disease: first report in the Arab region

JRSM Open ◽  
2020 ◽  
Vol 11 (2) ◽  
pp. 205427041989482
Author(s):  
Mohammed A Alzaid ◽  
Safa Eltahir ◽  
Muhammad Amin Ur Rahman ◽  
Wadha Alotaibi ◽  
Khalid Mobaireek
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Protein C ◽  
Surfactant Protein ◽  
Protein C Deficiency ◽  
Arab Region ◽  
Surfactant Protein C ◽  
Computed Tomographic ◽  
First Case ◽  
Childhood Interstitial Lung Disease

Background Surfactant protein C dysfunction is one of the causes of childhood interstitial lung disease but has not previously been reported in Arabian countries. Case presentation A six-year-old girl had presented at the age of eight months old with bronchiolitis followed by a persistent cough, dyspnea and hypoxaemia. She was found to have gastroesophageal reflux disease, but her symptoms did not resolve despite her therapy being optimised. Further tests, including a chest computed tomographic scan, lung biopsy and genetic testing, confirmed a diagnosis of surfactant protein C dysfunction. Conclusion We report the first case in the Arab region of childhood interstitial lung disease caused by surfactant protein C deficiency.

Clinical features and outcome of B-cell acute lymphoblastic leukemia in patients older than 9 years: A single center experience of 241 cases from AIIMS, New Delhi, India.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7082-7082 ◽  
Author(s):  
Atul Sharma ◽  
Sunu Lazar Cyriac ◽  
Siddharth Kumar Sahai ◽  
Sameer Bakhshi ◽  
Ritu Gupta ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Philadelphia Chromosome ◽  
Age Groups ◽  
Outcome Analysis ◽  
Total Leucocyte Count ◽  
Age Group ◽  
Single Center ◽  
Cell Acute Lymphoblastic Leukemia

7082 Background: Data on B cell Acute Lymphoblastic leukemia (ALL) in the poor prognostic age group of > 9 years from India is minimal. Methods: This is an analysis of patients of above 9 years that were diagnosed and treated from January 2000 to December 2010 at a single institute . All patients who completed at least 4 weeks of induction therapy were analysed for various outcomes. Results: Of the 241 newly registered patients, the median age was 19 years (Range 10-78 years) with an M:F ratio of 1.9:1. Out of this 47%, 25% & 28% patients belonged to 10-18, 19-30 & > 31 years age group respectively. Twenty seven (11.6%) and 5(2%) had CSF and testicular involvement respectively. Thirty nine per cent had a total leucocyte count (TLC) of above 30x109/L. Philadelphia chromosome (Ph) positivity was seen in 27% and was equally distributed among the different age groups. Patients available for outcome analysis were 213(88.4%). Complete remission rate (CRR) was 66.6% and induction mortality was 26.3%.At a median follow up of 65.8 months 5 year leukemia free survival was 30.5%. Seventy eight (55%) patients relapsed (median relapse time of 13.5 months, range 1.7 to 53.4 months) , 55% during maintenance phase. The 5 year overall survival (OS) was 30.3% with a median OS of 15.8 months. The OS was similar in 10-18 and 19-30 age groups (5 year OS 35% vs. 27.5%, p=0.641) but it was significantly lower in >31 years (5year OS 21%, p=0.008). Apart from this, extramedullary disease, not attaining a CR in 1st induction, albumin at presentation below 3.5gm% and TLC of >100x109/L were significant poor prognostic markers for survival. Conclusions: This is a large study of B-ALL outcomes in patients above 9 years from a single center in India. Patients above 30 years had a worse prognosis while the prognosis of 10-18 and 19-30 years age group were similar. Induction mortality was higher mainly because of advanced disease and poor performance status at presentation.

scholarly journals Interstitial Lung Disease in Werner Syndrome: A Case Report of a 55-Year-Old Male Patient

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Tiphaine Goletto ◽  
Flora Crockett ◽  
Selim Aractingi ◽  
Cecile Toper ◽  
Patricia Senet ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Werner Syndrome ◽  
Premature Aging ◽  
Causative Role ◽  
Average Life Expectancy ◽  
Telomere Attrition ◽  
Antifibrotic Therapy ◽  
First Case ◽  
Age Related

Werner syndrome (WS) is a progeroid or premature aging syndrome characterized by early onset of age-related pathologies and cancer. The average life expectancy of affected people is 52.8 years and tends to increase. The major causes of death are malignancy and myocardial infarction. Increased telomere attrition and decay are thought to play a causative role in the clinical and pathological manifestations of the disease. Although telomere length, with or without germline mutation, is known to be associated with interstitial lung disease, the latter is not associated with WS. To the best of our knowledge, we report the first case describing a WS patient with fatal ILD. This case suggests that older patients with WS could develop ILD. Clinical outcome of WS patients may thus be improved by counselling them regarding smoking cessation or other exposure and by proposing antifibrotic therapy.

scholarly journals Elotuzumab-induced interstitial lung disease: the first case report

2018 ◽  
Vol 48 (5) ◽  
pp. 491-494 ◽  
Author(s):  
Toru Tanaka ◽  
Yoshinobu Saito ◽  
Nariaki Kokuho ◽  
Hideto Tamura ◽  
Yasuhiro Terasaki ◽  
...  
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
First Case
Sign in / Sign up

Export Citation Format

Share Document